Prediction of drug-drug interactions arising from mechanism-based inactivation: Key input parameters and impact on risk assessment

Current Drug Metabolism

Volumn 12, Issue 9, 2011, Pages 871-890

  Wong, Simon G ^a  

^a AMGEN INC   (United States)

Author keywords

Drug drug interaction; Mechanism based inactivation; P450.; Risk assessment

Indexed keywords

ALPRAZOLAM; AZITHROMYCIN; BUSPIRONE; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; MEVINOLIN; MIBEFRADIL; MIDAZOLAM; NEFAZODONE; NIFEDIPINE; QUINIDINE; RIFAMPICIN; RITONAVIR; ROXITHROMYCIN; SAQUINAVIR; SIMVASTATIN; TRIAZOLAM; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; DRUG HALF LIFE; DRUG MECHANISM; ENZYME DEGRADATION; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RISK ASSESSMENT; STEADY STATE;

EID: 80053499643     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011797470146     Document Type: Article

References (110)

1. Grimm, S. W.; Einolf, H. J.; Hall, S. D.; He, K.; Lim, H. K.; Ling,K. H.; Lu, C.; Nomeir, A. A.; Seibert, E.; Skordos, K. W.; Tonn, G.R.; Van Horn, R.; Wang, R. W.; Wong, Y. N.; Yang, T. J.; Obach,R. S. The conduct of in vitro studies to address time-dependent inhibitionof drug-metabolizing enzymes: a perspective of the pharmaceuticalresearch and manufacturers of America. Drug. Metab.Dispos., 2009, 37 (7), 1355-70.
2. Mullins, M. E.; Horowitz, B. Z.; Linden, D. H.; Smith, G. W.;Norton, R. L.; Stump, J. Life-threatening interaction of mibefradiland beta-blockers with dihydropyridine calcium channel blockers.JAMA, 1998, 280 (2), 157-8. (Pubitemid 28498388)
3. Krayenbuhl, J. C.; Vozeh, S.; Kondo-Oestreicher, M.; Dayer, P.Drug-drug interactions of new active substances: mibefradil example.Eur. J. Clin. Pharmacol., 1999, 55 (8), 559-65. (Pubitemid 29489201)
4. Ernst, M. E.; Kelly, M. W. Mibefradil, a pharmacologically distinctcalcium antagonist. Pharmacotherapy, 1998, 18 (3), 463-85.
5. Einolf, H. J. Comparison of different approaches to predict metabolicdrug-drug interactions. Xenobiotica, 2007, 37 (10-11), 1257-94. (Pubitemid 350035530)
6. Fahmi, O. A.; Hurst, S.; Plowchalk, D.; Cook, J.; Guo, F.; Youdim,K.; Dickins, M.; Phipps, A.; Darekar, A.; Hyland, R.; Obach, R. S.Comparison of different algorithms for predicting clinical drugdruginteractions, based on the use of CYP3A4 in vitro data: predictionsof compounds as precipitants of interaction. Drug. Metab.Dispos., 2009, 37 (8), 1658-66.
7. Galetin, A.; Burt, H.; Gibbons, L.; Houston, J. B. Prediction oftime-dependent CYP3A4 drug-drug interactions: impact of enzymedegradation, parallel elimination pathways, and intestinal inhibition.Drug. Metab. Dispos., 2006, 34 (1), 166-75. (Pubitemid 43042658)
8. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K. Mechanismbasedinactivation of human cytochrome p450 enzymes and theprediction of drug-drug interactions. Drug. Metab. Dispos., 2007,35 (2), 246-55. (Pubitemid 46148737)
9. Wang, Y. H. Confidence assessment of the Simcyp time-basedapproach and a static mathematical model in predicting clinicaldrug-drug interactions for mechanism-based CYP3A inhibitors.Drug. Metab. Dispos., 2010, 38 (7), 1094-104.
10. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.;Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochromeP450 3A4 by therapeutic drugs. Clin. Pharmacokinet.,2005, 44 (3), 279-304. (Pubitemid 40477790)
11. Riley, R. J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition.Expert Opin. Drug Metab. Toxicol., 2007, 3 (1), 51-66. (Pubitemid 47315418)
12. Polasek, T. M.; Miners, J. O. In vitro approaches to investigatemechanism-based inactivation of CYP enzymes. Expert Opin.Drug Metab. Toxicol., 2007, 3 (3), 321-9. (Pubitemid 47316027)
13. Venkatakrishnan, K.; Obach, R. S.; Rostami-Hodjegan, A. Mechanism-based inactivation of human cytochrome P450 enzymes:strategies for diagnosis and drug-drug interaction risk assessment.Xenobiotica, 2007, 37 (10-11), 1225-56. (Pubitemid 350035532)
14. Zhou, Z. W.; Zhou, S. F. Application of mechanism-based CYPinhibition for predicting drug-drug interactions. Expert Opin. DrugMetab. Toxicol., 2009, 5 (6), 579-605.
15. Silverman, R. B. Mechanism-based enzyme inactivators. MethodsEnzymol., 1995, 249, 240-83.
16. Pessayre, D.; Larrey, D.; Vitaux, J.; Breil, P.; Belghiti, J.; Benhamou,J. P. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans.Biochem. Pharmacol., 1982, 31 (9), 1699-704. (Pubitemid 12102562)
17. Pessayre, D.; Descatoire, V.; Konstantinova-Mitcheva, M.; Wandscheer,J. C.; Cobert, B.; Level, R.; Benhamou, P. J.; Jaouen, M.;Mansuy, D. Self-induction by triacetyloleandomycin of its owntransformation into a metabolite forming a stable 456 nm-absorbingcomplex with cytochrome P-450. Biochem. Pharmacol., 1981, 30(6), 553-8. (Pubitemid 11155181)
18. Periti, P.; Mazzei, T.; Mini, E.; Novelli, A. Pharmacokinetic druginteractions of macrolides. Clin. Pharmacokinet., 1992, 23 (2),106-31.
19. Jones, D. R.; Gorski, J. C.; Hamman, M. A.; Mayhew, B. S.; Rider,S.; Hall, S. D. Diltiazem inhibition of cytochrome P-450 3A activityis due to metabolite intermediate complex formation. J. Pharmacol.Exp. Ther., 1999, 290 (3), 1116-25. (Pubitemid 29400251)
20. Ma, B.; Prueksaritanont, T.; Lin, J. H. Drug interactions with calciumchannel blockers: possible involvement of metaboliteintermediatecomplexation with CYP3A. Drug. Metab. Dispos.,.2000, 28 (2), 125-30. (Pubitemid 30068994)
21. Ernest, C. S., 2nd; Hall, S. D.; Jones, D. R. Mechanism-basedinactivation of CYP3A by HIV protease inhibitors. J. Pharmacol.Exp. Ther., 2005, 312 (2), 583-91. (Pubitemid 40189555)
22. Prueksaritanont, T.; Ma, B.; Tang, C.; Meng, Y.; Assang, C.; Lu,P.; Reider, P. J.; Lin, J. H.; Baillie, T. A. Metabolic interactions betweenmibefradil and HMG-CoA reductase inhibitors: an in vitroinvestigation with human liver preparations. Br.J. Clin. Pharmacol.,1999, 47 (3), 291-8. (Pubitemid 29131344)
23. Fontana, E.; Dansette, P. M.; Poli, S. M. Cytochrome p450 enzymesmechanism based inhibitors: common sub-structures and reactivity.Curr. Drug. Metab., 2005, 6 (5), 413-54. (Pubitemid 41300789)
24. Kalgutkar, A. S.; Obach, R. S.; Maurer, T. S. Mechanism-basedinactivation of cytochrome P450 enzymes: chemical mechanisms,structure-activity relationships and relationship to clinical drugdruginteractions and idiosyncratic adverse drug reactions. Curr.Drug. Metab., 2007, 8 (5), 407-47. (Pubitemid 47603408)
25. Walsh, C.; Cromartie, T.; Marcotte, P.; Spencer, R. Suicide substratesfor flavoprotein enzymes. Methods Enzymol., 1978, 53, 437-48.
26. Waley, S. G. Kinetics of suicide substrates. Biochem. J., 1980, 185(3), 771-3.
27. Tatsunami, S.; Yago, N.; Hosoe, M. Kinetics of suicide substrates.Steady-state treatments and computer-aided exact solutions. Biochim.Biophys. Acta, 1981, 662 (2), 226-35.
28. Tudela, J.; Garcia Canovas, F.; Varon, R.; Garcia Carmona, F.;Galvez, J.; Lozano, J. A. Transient-phase kinetics of enzyme inactivationinduced by suicide substrates. Biochim. Biophys. Acta,1987, 912 (3), 408-16. (Pubitemid 17066100)
29. Mayhew, B. S.; Jones, D. R.; Hall, S. D. An in vitro model forpredicting in vivo inhibition of cytochrome P450 3A4 by metabolicintermediate complex formation. Drug. Metab. Dispos., 2000, 28(9), 1031-7. (Pubitemid 30660356)
30. Wang, Y. H.; Jones, D. R.; Hall, S. D. Prediction of cytochromeP450 3A inhibition by verapamil enantiomers and their metabolites.Drug. Metab. Dispos., 2004, 32 (2), 259-66. (Pubitemid 38176944)
31. Jung, M. J.; Metcalf, B. W. Catalytic inhibition of gammaaminobutyricacid - alpha-ketoglutarate transaminase of bacterialorigin by 4-aminohex-5-ynoic acid, a substrate analog. Biochem.Biophys. Res. Commun., 1975, 67 (1), 301-6.
32. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J. C.; Clarke, S. E.;Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. A criticalevaluation of the experimental design of studies of mechanismbased enzyme inhibition, with implications for in vitro-in vivo extrapolation.Curr. Drug. Metab., 2006, 7 (3), 315-34.
33. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan,A. Kinetic values for mechanism-based enzyme inhibition: assessingthe bias introduced by the conventional experimental protocol.Eur. J. Pharm. Sci., 2005, 26 (3-4), 334-40. (Pubitemid 41278639)
34. Wilkinson, G. R.; Shand, D. G. Commentary: a physiological approachto hepatic drug clearance. Clin. Pharmacol. Ther., 1975, 18(4), 377-90.
35. Venkatakrishnan, K.; Obach, R. S. Drug-drug interactions viamechanism-based cytochrome P450 inactivation: points to considerfor risk assessment from in vitro data and clinical pharmacologicevaluation. Curr. Drug. Metab., 2007, 8 (5), 449-62. (Pubitemid 47603409)
36. Correia, M. A. Cytochrome P450 turnover. Methods Enzymol.,1991, 206, 315-25.
37. Roberts, B. J.; Song, B. J.; Soh, Y.; Park, S. S.; Shoaf, S. E. Ethanolinduces CYP2E1 by protein stabilization. Role of ubiquitinconjugation in the rapid degradation of CYP2E1. J. Biol. Chem.,1995, 270 (50), 29632-5.
38. Watkins, P. B.; Wrighton, S. A.; Schuetz, E. G.; Maurel, P.; Guzelian,P. S. Macrolide antibiotics inhibit the degradation of the glucocorticoid- responsive cytochrome P-450p in rat hepatocytes invivo and in primary monolayer culture. J. Biol. Chem., 1986, 261(14), 6264-71. (Pubitemid 17204131)
39. Pichard, L.; Fabre, I.; Daujat, M.; Domergue, J.; Joyeux, H.; Maurel,P. Effect of corticosteroids on the expression of cytochromesP450 and on cyclosporin A oxidase activity in primary cultures ofhuman hepatocytes. Mol. Pharmacol., 1992, 41 (6), 1047-55. (Pubitemid 23026103)
40. Maurel, P. The use of adult human hepatocytes in primary cultureand other in vitro systems to investigate drug metabolism in man.Adv. Drug Deliv. Rev., 1996, 22, 105-132. (Pubitemid 26423600)
41. Yang, J.; Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.;Rostami-Hodjegan, A. Cytochrome p450 turnover: regulation ofsynthesis and degradation, methods for determining rates, and implicationsfor the prediction of drug interactions. Curr. Drug. Metab.,2008, 9 (5), 384-94.
42. Renwick, A. B.; Watts, P. S.; Edwards, R. J.; Barton, P. T.; Guyonnet,I.; Price, R. J.; Tredger, J. M.; Pelkonen, O.; Boobis, A. R.;Lake, B. G. Differential maintenance of cytochrome P450 enzymesin cultured precision-cut human liver slices. Drug. Metab. Dispos.,2000, 28 (10), 1202-9.
43. Fromm, M. F.; Busse, D.; Kroemer, H. K.; Eichelbaum, M. Differentialinduction of prehepatic and hepatic metabolism of verapamilby rifampin. Hepatology, 1996, 24 (4), 796-801. (Pubitemid 26334275)
44. Tran, J. Q.; Kovacs, S. J.; McIntosh, T. S.; Davis, H. M.; Martin,D. E. Morning spot and 24-hour urinary 6 beta-hydroxycortisol tocortisol ratios: intraindividual variability and correlation under basalconditions and conditions of CYP 3A4 induction. J. Clin.Pharmacol., 1999, 39 (5), 487-94. (Pubitemid 29356469)
45. Greenblatt, D. J.; von Moltke, L. L.; Harmatz, J. S.; Chen, G.;Weemhoff, J. L.; Jen, C.; Kelley, C. J.; LeDuc, B. W.; Zinny, M.A. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther., 2003, 74(2), 121-9. (Pubitemid 36951809)
46. Quinney, S. K.; Zhang, X.; Lucksiri, A.; Gorski, J. C.; Li, L.; Hall,S. D. Physiologically based pharmacokinetic model of mechanismbasedinhibition of CYP3A by clarithromycin. Drug. Metab. Dispos.,2010, 38 (2), 241-8.
47. Imai, H.; Kotegawa, T.; Tsutsumi, K.; Morimoto, T.; Eshima, N.;Nakano, S.; Ohashi, K. The recovery time-course of CYP3A afterinduction by St John's wort administration. Br. J. Clin. Pharmacol.,2008, 65 (5), 701-7. (Pubitemid 351535099)
48. Kanamitsu, S.; Ito, K.; Sugiyama, Y. Quantitative prediction of invivo drug-drug interactions from in vitro data based on physiologicalpharmacokinetics: use of maximum unbound concentration ofinhibitor at the inlet to the liver. Pharm. Res., 2000, 17 (3), 336-43. (Pubitemid 30225138)
49. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Gaman, E. A.;Houston, J. B.; Tremaine, L. M. The utility of in vitro cytochromeP450 inhibition data in the prediction of drug-drug interactions. J.Pharmacol. Exp. Ther., 2006, 316 (1), 336-48. (Pubitemid 41832613)
50. Venkatakrishnan, K.; Obach, R. S. In vitro-in vivo extrapolation ofCYP2D6 inactivation by paroxetine: prediction of nonstationarypharmacokinetics and drug interaction magnitude. Drug. Metab.Dispos., 2005, 33 (6), 845-52. (Pubitemid 40686639)
51. Lin, J. H.; Chiba, M.; Baillie, T. A. Is the role of the small intestinein first-pass metabolism overemphasized? Pharmacol Rev., 1999,51 (2), 135-58.
52. Galetin, A.; Gertz, M.; Houston, J. B. Potential role of intestinalfirst-pass metabolism in the prediction of drug-drug interactions.Expert Opin. Drug Metab. Toxicol., 2008, 4 (7), 909-22.
53. Chen, J.; Pang, K. S. Effect of flow on first-pass metabolism ofdrugs: single pass studies on 4-methylumbelliferone conjugation inthe serially perfused rat intestine and liver preparations. J. Pharmacol.Exp. Ther., 1997, 280 (1), 24-31. (Pubitemid 27171383)
54. Hirayama, H.; Pang, K. S. First-pass metabolism of gentisamide:influence of intestinal metabolism on hepatic formation of conjugates.Studies in the once-through vascularly perfused rat intestineliverpreparation. Drug. Metab. Dispos., 1990, 18 (5), 580-7. (Pubitemid 20348844)
55. Xu, X.; Hirayama, H.; Pang, K. S. First-pass metabolism of salicylamide.Studies in the once-through vascularly perfused rat intestine-liver preparation. Drug. Metab. Dispos., 1989, 17 (5), 556-63. (Pubitemid 19244921)
56. Paine, M. F.; Shen, D. D.; Kunze, K. L.; Perkins, J. D.; Marsh, C.L.; McVicar, J. P.; Barr, D. M.; Gillies, B. S.; Thummel, K. E.First-pass metabolism of midazolam by the human intestine. Clin.Pharmacol. Ther., 1996, 60 (1), 14-24. (Pubitemid 26279216)
57. Campa, J.; Reynolds, T., The hepatic circulation. 1988.
58. Gertz, M.; Davis, J. D.; Harrison, A.; Houston, J. B.; Galetin, A.Grapefruit juice-drug interaction studies as a method to assess theextent of intestinal availability: utility and limitations. Curr. Drug.Metab., 2008, 9 (8), 785-95.
59. Lown, K. S.; Bailey, D. G.; Fontana, R. J.; Janardan, S. K.; Adair,C. H.; Fortlage, L. A.; Brown, M. B.; Guo, W.; Watkins, P. B.Grapefruit juice increases felodipine oral availability in humans bydecreasing intestinal CYP3A protein expression. J Clin Invest. >1997, 99 (10), 2545-53. (Pubitemid 27227734)
60. Galetin, A.; Hinton, L. K.; Burt, H.; Obach, R. S.; Houston, J. B.Maximal inhibition of intestinal first-pass metabolism as a pragmaticindicator of intestinal contribution to the drug-drug interactionsfor CYP3A4 cleared drugs. Curr. Drug. Metab., 2007, 8 (7),685-93. (Pubitemid 47591312)
61. Guest, E. J.; Aarons, L.; Houston, J. B.; Rostami-Hodjegan, A.;Galetin, A. Critique of the two-fold measure of prediction successfor ratios: application for the assessment of drug-drug interactions.Drug. Metab. Dispos.,. 2011.
62. Tang, C.; Prueksaritanont, T. Use of in vivo animal models to assesspharmacokinetic drug-drug interactions. Pharm. Res., 2010, 27(9), 1772-87.
63. Wong, S. G.; Fan, P. W.; Subramanian, R.; Tonn, G. R.; Henne, K.R.; Johnson, M. G.; Tadano Lohr, M.; Wong, B. K. Bioactivationof a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/Dprostanoidreceptor antagonist leads to mechanism-based CYP3Ainactivation: glutathione adduct characterization and prediction ofin vivo drug-drug interaction. Drug. Metab. Dispos., 2010, 38 (5),841-50.
64. Tang, W.; Stearns, R. A.; Wang, R. W.; Miller, R. R.; Chen, Q.;Ngui, J.; Bakshi, R. K.; Nargund, R. P.; Dean, D. C.; Baillie, T. A.Assessing and minimizing time-dependent inhibition of cytochromeP450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. Xenobiotica, 2008, 38 (11), 1437-51.
65. Chang, S. Y.; Fancher, R. M.; Zhang, H.; Gan, J. Mechanism- basedinhibition of human cytochrome P4503A4 by domperidone. Xenobiotica,2010, 40 (2), 138-45.
66. Bois, F. Y. Physiologically based modelling and prediction of druginteractions. Basic Clin Pharmacol Toxicol., 2010, 106 (3), 154-61.
67. Zhao, P.; Zhang, L.; Grillo, J. A.; Liu, Q.; Bullock, J. M.; Moon, Y.J.; Song, P.; Brar, S. S.; Madabushi, R.; Wu, T. C.; Booth, B. P.;Rahman, N. A.; Reynolds, K. S.; Berglund, E. G.; Lesko, L. J.;Huang, S. M. Applications of Physiologically Based Pharmacokinetic(PBPK) Modeling and Simulation During Regulatory Review.Clin. Pharmacol. Ther., 2010.
68. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Nakajima, Y.; Sugiyama, Y.Quantitative prediction of in vivo drug clearance and drug interactionsfrom in vitro data on metabolism, together with binding andtransport. Annu Rev Pharmacol Toxicol. 1998, 38, 461-99. (Pubitemid 28231503)
69. Ito, K.; Ogihara, K.; Kanamitsu, S.; Itoh, T. Prediction of the invivo interaction between midazolam and macrolides based on in vitrostudies using human liver microsomes. Drug. Metab. Dispos.,2003, 31 (7), 945-54. (Pubitemid 36759066)
70. Yamano, K.; Yamamoto, K.; Katashima, M.; Kotaki, H.; Takedomi,S.; Matsuo, H.; Ohtani, H.; Sawada, Y.; Iga, T. Prediction ofmidazolam-CYP3A inhibitors interaction in the human liver fromin vivo/in vitro absorption, distribution, and metabolism data. Drug.Metab. Dispos., 2001, 29 (4 Pt 1), 443-52. (Pubitemid 32275559)
71. Zhang, X.; Galinsky, R. E.; Kimura, R. E.; Quinney, S. K.; Jones,D. R.; Hall, S. D. Inhibition of CYP3A by erythromycin: in vitro-invivo correlation in rats. Drug. Metab. Dispos., 2009, 38 (1), 61-72.
72. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp population-based ADME simulator.Expert Opin. Drug Metab. Toxicol., 2009, 5 (2), 211-23.
73. Duan, J. Z.; Jackson, A. J.; Zhao, P. Bioavailability Considerationsin Evaluating Drug-Drug Interactions Using the Population PharmacokineticApproach. J. Clin. Pharmacol., .
74. Guest, E. J.; Rowland-Yeo, K.; Rostami-Hodjegan, A.; Tucker, G.T.; Houston, J. B.; Galetin, A. Assessment of algorithms for predictingdrug-drug interactions via inhibition mechanisms: comparisonof dynamic and static models. Br. J. Clin. Pharmacol., 2011,71 (1), 72-87.
75. Pourbaix, S.; Desager, J. P.; Hulhoven, R.; Smith, R. B.; Harvengt,C. Pharmacokinetic consequences of long term coadministration ofcimetidine and triazolobenzodiazepines, alprazolam and triazolam,in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol., 1985,23 (8), 447-51. (Pubitemid 15004913)
76. Friedman, H.; Greenblatt, D. J.; Burstein, E. S.; Scavone, J. M.;Harmatz, J. S.; Shader, R. I. Triazolam kinetics: interaction withcimetidine, propranolol, and the combination. J. Clin. Pharmacol.,1988, 28 (3), 228-33. (Pubitemid 19014770)
77. Kirch, W.; Ramsch, K.; Janisch, H. D.; Ohnhaus, E. E. The influenceof two histamine H2-receptor antagonists, cimetidine andranitidine, on the plasma levels and clinical effect of nifedipine andmetoprolol. Arch. Toxicol. Suppl., 1984, 7, 256-9. (Pubitemid 15202427)
78. Azie, N. E.; Brater, D. C.; Becker, P. A.; Jones, D. R.; Hall, S. D.The interaction of diltiazem with lovastatin and pravastatin. Clin.Pharmacol. Ther., 1998, 64 (4), 369-77. (Pubitemid 28473762)
79. Bailey, D. G.; Bend, J. R.; Arnold, J. M.; Tran, L. T.; Spence, J. D.Erythromycin-felodipine interaction: magnitude, mechanism, andcomparison with grapefruit juice. Clin. Pharmacol. Ther., 1996, 60(1), 25-33. (Pubitemid 26279217)
80. Damkier, P.; Hansen, L. L.; Brosen, K. Effect of diclofenac, disulfiram,itraconazole, grapefruit juice and erythromycin on the pharmacokineticsof quinidine. Br.J. Clin. Pharmacol., 1999, 48 (6),829-38.
81. Kosuge, K.; Nishimoto, M.; Kimura, M.; Umemura, K.; Nakashima,M.; Ohashi, K. Enhanced effect of triazolam with diltiazem.Br.J. Clin. Pharmacol., 1997, 43 (4), 367-72. (Pubitemid 27187475)
82. Kantola, T.; Kivisto, K. T.; Neuvonen, P. J. Erythromycin andverapamil considerably increase serum simvastatin and simvastatinacid concentrations. Clin. Pharmacol. Ther., 1998, 64 (2), 177-82. (Pubitemid 28423853)
83. Bailey, D. G.; Arnold, J. M.; Munoz, C.; Spence, J. D. Grapefruitjuice-felodipine interaction: mechanism, predictability, and effectof naringin. Clin. Pharmacol. Ther., 1993, 53 (6), 637-42.
84. Canafax, D. M.; Graves, N. M.; Hilligoss, D. M.; Carleton, B. C.;Gardner, M. J.; Matas, A. J. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation, 1991, 51(5), 1014-8.
85. Trapnell, C. B.; Narang, P. K.; Li, R.; Lavelle, J. P. Increasedplasma rifabutin levels with concomitant fluconazole therapy inHIV-infected patients. Ann. Intern. Med., 1996, 124 (6), 573-6. (Pubitemid 26085059)
86. Varhe, A.; Olkkola, K. T.; Neuvonen, P. J. Fluconazole, but notterbinafine, enhances the effects of triazolam by inhibiting its metabolism.Br.J. Clin. Pharmacol., 1996, 41 (4), 319-23. (Pubitemid 26114819)
87. Phillips, J. P.; Antal, E. J.; Smith, R. B. A pharmacokinetic druginteraction between erythromycin and triazolam. J Clin Psychopharmacol.1986, 6 (5), 297-9.
88. Lasher, T. A.; Fleishaker, J. C.; Steenwyk, R. C.; Antal, E. J.Pharmacokinetic pharmacodynamic evaluation of the combinedadministration of alprazolam and fluoxetine. Psychopharmacology(Berl)., 1991, 104 (3), 323-7.
89. Greenblatt, D. J.; Preskorn, S. H.; Cotreau, M. M.; Horst, W. D.;Harmatz, J. S. Fluoxetine impairs clearance of alprazolam but notof clonazepam. Clin. Pharmacol. Ther.,1992, 52 (5), 479-86.
90. Wright, C. E.; Lasher-Sisson, T. A.; Steenwyk, R. C.; Swanson, C.N. A pharmacokinetic evaluation of the combined administration oftriazolam and fluoxetine. Pharmacotherapy. 1992, 12 (2), 103-6.
91. Fleishaker, J. C.; Hulst, L. K. A pharmacokinetic and pharmacodynamicevaluation of the combined administration of alprazolam andfluvoxamine. Eur. J. Clin. Pharmacol.,. 1994, 46 (1), 35-9. (Pubitemid 24067586)
92. Lamberg, T. S.; Kivisto, K. T.; Neuvonen, P. J. Effects of verapamiland diltiazem on the pharmacokinetics and pharmacodynamicsof buspirone. Clin. Pharmacol. Ther., 1998, 63 (6), 640-5. (Pubitemid 28327891)
93. Backman, J. T.; Wang, J. S.; Wen, X.; Kivisto, K. T.; Neuvonen, P.J. Mibefradil but not isradipine substantially elevates the plasmaconcentrations of the CYP3A4 substrate triazolam. Clin. Pharmacol.Ther., 1999, 66 (4), 401-7. (Pubitemid 29494133)
94. Lefebvre, R. A.; Van Peer, A.; Woestenborghs, R. Influence ofitraconazole on the pharmacokinetics and electrocardiographic effectsof astemizole. Br.J. Clin. Pharmacol.,> 1997, 43 (3), 319-22. (Pubitemid 27116073)
95. Yasui, N.; Otani, K.; Kaneko, S.; Ohkubo, T.; Osanai, T.; Sugawara,K.; Chiba, K.; Ishizaki, T. A kinetic and dynamic study oforal alprazolam with and without erythromycin in humans: in vivoevidence for the involvement of CYP3A4 in alprazolam metabolism.Clin. Pharmacol. Ther., 1996, 59 (5), 514-9. (Pubitemid 26193890)
96. Kivisto, K. T.; Lamberg, T. S.; Neuvonen, P. J. Interactions ofbuspirone with itraconazole and rifampicin: effects on the pharmacokineticsof the active 1-(2-pyrimidinyl)-piperazine metabolite ofbuspirone. Pharmacol. Toxicol., 1999, 84 (2), 94-7. (Pubitemid 29088370)
97. Kantola, T.; Kivisto, K. T.; Neuvonen, P. J. Effect of itraconazoleon cerivastatin pharmacokinetics. Eur. J. Clin. Pharmacol., 1999,54 (11), 851-5.
98. Gomez, D. Y.; Wacher, V. J.; Tomlanovich, S. J.; Hebert, M. F.;Benet, L. Z. The effects of ketoconazole on the intestinal metabolismand bioavailability of cyclosporine. Clin. Pharmacol. Ther.,1995, 58 (1), 15-9.
99. Greenblatt, D. J.; von Moltke, L. L.; Harmatz, J. S.; Counihan, M.;Graf, J. A.; Durol, A. L.; Mertzanis, P.; Duan, S. X.; Wright, C. E.;Shader, R. I. Inhibition of triazolam clearance by macrolide antimicrobialagents: in vitro correlates and dynamic consequences. Clin.Pharmacol. Ther., 1998, 64 (3), 278-85. (Pubitemid 28462288)
100. Ito, K.; Brown, H. S.; Houston, J. B. Database analyses for theprediction of in vivo drug-drug interactions from in vitro data. Br.J.Clin. Pharmacol., 2004, 57 (4), 473-86. (Pubitemid 38519653)
101. Heinig, R.; Adelmann, H. G.; Ahr, G. The effect of ketoconazoleon the pharmacokinetics, pharmacodynamics and safety of nisoldipine.Eur. J. Clin. Pharmacol., 1999, 55 (1), 57-60. (Pubitemid 29144101)
102. Floren, L. C.; Bekersky, I.; Benet, L. Z.; Mekki, Q.; Dressler, D.;Lee, J. W.; Roberts, J. P.; Hebert, M. F. Tacrolimus oral bioavailabilitydoubles with coadministration of ketoconazole. Clin. Pharmacol.Ther., 1997, 62 (1), 41-9. (Pubitemid 27327098)
103. Tortorice, K. L.; Heim-Duthoy, K. L.; Awni, W. M.; Rao, K. V.;Kasiske, B. L. The effects of calcium channel blockers on cyclosporineand its metabolites in renal transplant recipients. Ther.Drug Monit., 1990, 12 (4), 321-8. (Pubitemid 20240635)
104. Backman, J. T.; Kivisto, K. T.; Olkkola, K. T.; Neuvonen, P. J. Thearea under the plasma concentration-time curve for oral midazolamis 400-fold larger during treatment with itraconazole than with rifampicin.Eur. J. Clin. Pharmacol., 1998, 54 (1), 53-8. (Pubitemid 28189400)
105. Bowles, S. K.; Reeves, R. A.; Cardozo, L.; Edwards, D. J. Evaluationof the pharmacokinetic and pharmacodynamic interaction betweenquinidine and nifedipine. J. Clin. Pharmacol., 1993, 33 (8),727-31. (Pubitemid 23260399)
106. Gorski, J. C.; Jones, D. R.; Haehner-Daniels, B. D.; Hamman, M.A.; O'Mara, E. M., Jr.; Hall, S. D. The contribution of intestinal andhepatic CYP3A to the interaction between midazolam andclarithromycin. Clin. Pharmacol. Ther., 1998, 64 (2), 133-43. (Pubitemid 28423848)
107. Barbhaiya, R. H.; Shukla, U. A.; Kroboth, P. D.; Greene, D. S.Coadministration of nefazodone and benzodiazepines: II. A pharmacokineticinteraction study with triazolam. J. Clin. Psychopharmacol.,1995, 15 (5), 320-6.
108. Canafax, D. M.; Graves, N. M.; Hilligoss, D. M.; Carleton, B. C.;Gardner, M. J.; Matas, A. J. Increased cyclosporine levels as a resultof simultaneous fluconazole and cyclosporine therapy in renaltransplant recipients: a double-blind, randomized pharmacokineticand safety study. Transplant Proc., 1991, 23 (1 Pt 2), 1041-2.
109. Freeman, D. J.; Martell, R.; Carruthers, S. G.; Heinrichs, D.; Keown,P. A.; Stiller, C. R. Cyclosporin-erythromycin interaction innormal subjects. Br.J. Clin. Pharmacol., 1987, 23 (6), 776-8.
110. Ahonen, J.; Olkkola, K. T.; Neuvonen, P. J. Effect of itraconazoleand terbinafine on the pharmacokinetics and pharmacodynamics ofmidazolam in healthy volunteers. Br.J. Clin. Pharmacol., 1995, 40(3), 270-2.